Immune Thrombocytopenia Market Report 2026

Immune Thrombocytopenia Market Overview

• Immune Thrombocytopenia market size has reached to $3.61 billion in 2025 • Expected to grow to $4.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.5% • Growth Driver: Rise In Autoimmune Diseases Driving The Growth Of The Market Due To Increasing Platelet Destruction • Market Trend: Advancements In Intravenous Therapies For Autoimmune Disease Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Immune Thrombocytopenia Market?

Immune thrombocytopenia refers to a rare autoimmune bleeding disorder where the immune system mistakenly destroys platelets, which are essential for blood clotting. This leads to a low platelet count, hindering the blood's ability to form clots. Symptoms include easy bruising, bleeding, and a rash of small red spots. The main types of immune thrombocytopenia are primary immune thrombocytopenia (ITP), secondary immune thrombocytopenia, and acquired immune thrombocytopenia. Primary ITP is a condition in which the immune system mistakenly targets and destroys platelets in the blood. Treatment options include intravenous immunoglobulin, thrombopoietin receptor agonists, and immunosuppressive therapy, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Immune Thrombocytopenia Market Growth Forecast?

The immune thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to development of novel biologics and oral agents, growing focus on long-term disease management, increasing adoption of outpatient and home-based care, expansion of precision medicine in autoimmune disorders, rising healthcare access in emerging markets. Major trends in the forecast period include increasing adoption of targeted immunotherapies, growing use of thrombopoietin receptor agonists, rising focus on personalized treatment approaches, expansion of chronic itp management strategies, increasing awareness and early diagnosis of itp.

Global Immune Thrombocytopenia Market Segmentation

1) By Type: Primary Immune Thrombocytopenia, Secondary Immune Thrombocytopenia, Acquired Immune Thrombocytopenia 2) By Treatment Type: Intravenous Immunoglobulin, Thrombopoietin Receptor Agonists, Immunosuppressive Therapy 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Primary Immune Thrombocytopenia: Acute Primary ITP, Chronic Primary ITP, Persistent Primary ITP 2) By Secondary Immune Thrombocytopenia: Drug-Induced ITP, Infection-Associated ITP, Autoimmune Disorder-Related ITP 3) By Acquired Immune Thrombocytopenia: Immune-Mediated Acquired ITP, Non-Immune Acquired ITP

What Is The Driver Of The Immune Thrombocytopenia Market?

The growing prevalence of autoimmune diseases is expected to propel the growth of the immune thrombocytopenia market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, treating them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is linked to genetic predispositions, environmental factors, lifestyle changes, and increasing awareness leading to better diagnosis. Autoimmune diseases cause immune thrombocytopenia by triggering the immune system to attack and destroy the body's platelets or impair their production in the bone marrow. For instance, in November 2023, according to the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization, an estimated 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune disease in 2023. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the immune thrombocytopenia industry.

Key Players In The Global Immune Thrombocytopenia Market

Major companies operating in the immune thrombocytopenia market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Intas Pharmaceuticals Ltd., CSL Behring, Grifols, UCB Pharma, Kyowa Kirin, Sobi (Swedish Orphan Biovitrum), 3SBio Inc., Biotest AG, Shionogi & Co. Ltd., Ligand Pharmaceuticals, Rigel Pharmaceuticals, Symphogen, Hansa Biopharma, Argenx.

Global Immune Thrombocytopenia Market Trends and Insights

Major companies operating in the immune thrombocytopenia market are prioritizing therapeutic advancements, particularly in intravenous therapy, to enhance treatment effectiveness, accelerate response times, improve patient adherence, and address unmet medical needs in thrombocytopenia management. Intravenous (IV) therapy is a medical treatment that involves delivering fluids, medications, or nutrients directly into a patient's vein through an IV line. For instance, in March 2024, Argenx SE, a Netherlands-based biotechnology company, announced that the Japan Ministry of Health, Labor, and Welfare (MHLW) had approved VYVGART for intravenous administration in adults with primary immune thrombocytopenia (ITP). This approval represents a major advancement in treatment options, offering a targeted approach with rapid effectiveness and sustained platelet response, addressing critical unmet needs in autoimmune disease management.

What Are Latest Mergers And Acquisitions In The Immune Thrombocytopenia Market?

In December 2024, Keros Therapeutics Inc., a US-based biopharmaceutical company, partnered with Takeda Pharmaceutical Industries Ltd. to develop and commercialize elritercept, a therapy targeting disorders linked to dysfunctional TGF-β signaling, including thrombocytopenia and other rare diseases. Takeda Pharmaceutical Industries Ltd. is a Japan-based biopharmaceutical company specializing in innovative treatments for thrombocytopenia and other rare diseases.

Regional Outlook

North America was the largest region in the immune thrombocytopenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Immune Thrombocytopenia Market?

The immune thrombocytopenia market consists of revenues earned by entities by providing services such as blood or platelet transfusions, splenectomy, plasma exchange, monitoring, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The immune thrombocytopenia market also includes sales of pharmaceutical drugs, diagnostic kits and reagents, medical devices, platelet transfusion products, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Immune Thrombocytopenia Market Report 2026?

The immune thrombocytopenia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the immune thrombocytopenia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.